World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
37883
World Ranking
10374
National Ranking
5337

Carol Aghajanian publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Carol Aghajanian sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 585 publications — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Carol Aghajanian D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Carol Aghajanian sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Carol Aghajanian is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research focuses largely on medicine, with significant contributions to biochemistry, genetics, and molecular biology. Within these fields, their work extends into key subfields including reproductive medicine, oncology, obstetrics and gynecology, molecular biology, and genetics.

The primary topics covered by their research include ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, and genetic factors in colorectal cancer.

Carol Aghajanian has published extensively, with a strong presence in the following venues:

  • Gynecologic Oncology (98 publications)
  • Journal of Clinical Oncology (45 publications)
  • International Journal of Gynecological Cancer (11 publications)
  • Clinical Cancer Research (9 publications)
  • Annals of Oncology (9 publications)

Their recent research papers include:

  • Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer, 2023, New England Journal of Medicine
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients, 2022, Cell
  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer, 2020, Journal of Clinical Oncology
  • Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial, 2022, Journal of Clinical Oncology
  • Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39), 2021, Journal of Clinical Oncology

Frequent collaborators in Carol Aghajanian's work include:

  • Britta Weigelt
  • Nadeem R. Abu-Rustum
  • Roisin E. O'Cearbhaill
  • Rachel N. Grisham
  • Alexia Iasonos

Best Publications

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Carol Aghajanian;Stephanie V. Blank;Barbara A. Goff;Patricia L. Judson

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

    Martee L. Hensley;Robert Maki;E. Venkatraman;Gennifer Geller

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

    Dennis S. Chi;Eric L. Eisenhauer;Oliver Zivanovic;Yukio Sonoda

  • A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

    Carol Aghajanian;Steven Soignet;Don S. Dizon;Christine S. Pien

  • Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

    Alejandro Jiménez-Sánchez;Danish Memon;Stephane Pourpe;Harini Veeraraghavan

  • The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center.

    Nadeem R. Abu-Rustum;Kaled Alektiar;Alexia Iasonos;Gali Lev

  • Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

    Vicky Makker;Drew Rasco;Nicholas J Vogelzang;Marcia S Brose

  • Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.

    Dennis S. Chi;Kristina McCaughty;John P. Diaz;Jae Huh

  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

    Vicky Makker;Matthew H. Taylor;Carol Aghajanian;Ana Oaknin

  • The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

    Eric L. Eisenhauer;Nadeem R. Abu-Rustum;Yukio Sonoda;Douglas A. Levine

  • Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer

    Krishnansu S. Tewari;Robert A. Burger;Danielle Enserro;Barbara M. Norquist

  • Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

    Carol Aghajanian;Michael W. Sill;Kathleen M. Darcy;Benjamin Greer

  • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study

    Robert L. Coleman;Michael W. Sill;Katherine Bell-McGuinn;Carol Aghajanian

  • Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

    Paul Sabbatini;Takemasa Tsuji;Luis Ferran;Erika Ritter

  • Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

    Carol Aghajanian;Barbara Goff;Lawrence R. Nycum;Yan V. Wang

  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

    Bastien Nguyen;Christopher Fong;Anisha Luthra;Shaleigh A. Smith

Frequent Co-Authors

Nadeem R. Abu-Rustum
Nadeem R. Abu-Rustum Memorial Sloan Kettering Cancer Center
Dennis S. Chi
Dennis S. Chi Memorial Sloan Kettering Cancer Center
Richard R. Barakat
Richard R. Barakat Northwell Health
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
David M. Hyman
David M. Hyman Memorial Sloan Kettering Cancer Center
Robert A. Soslow
Robert A. Soslow Memorial Sloan Kettering Cancer Center
Yukio Sonoda
Yukio Sonoda Memorial Sloan Kettering Cancer Center
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine but want flexible options or alternate career paths, there are many online healthcare degrees to explore. For those eager to start a nursing career, you might be looking for the easiest rn program to get into or seeking nursing school that don't require teas to simplify the admissions process.

Beyond direct patient care, non-clinical roles are a great alternative. Medical billing and coding online schools prepare students for essential administrative jobs, often allowing you to work remotely. If you’re interested in leadership roles within healthcare settings, a healthcare administration degree online accredited can help accelerate your path to upper management.

These online programs are designed to fit your lifestyle, with options that require no entrance exams and offer flexible schedules. This makes it easier to balance education with other commitments while still progressing toward a rewarding healthcare career.

Best Scientists Citing Carol Aghajanian

Trending Scientists

Recently Published Articles